Global Anticoagulant Market, By Drug Class (Vitamin K Antagonist (Warfarin), Non-VKA Oral Anticoagulants (NOACS), Heparin and LMWH, Thrombin Inhibitors (Dabigatran)), Therapeutic Areas (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Atrial Fibrillation, Heart Attack, Stroke, Unstable Angina, Hip Or Knee Replacement Surgery, Others), Route Of Administration (Oral, Parenteral), End User (Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Anticoagulant Market Analysis and Size
According to the Centers for Disease Control and Prevention, men and women are equally affected by von Willebrand disease (VWD), which affects up to 1% of the general population. Between 2012 and 2016, over 14,600 men, women, and children were treated for von Willebrand disease (VWD) at haemophilia treatment centres; approximately two-thirds of these were women and girls. As a result, the global market is expected to be driven by an increase in cases of coagulation disorders during the forecast period.
Data Bridge Market Research analyses that the anticoagulant market which is USD 60.90 million in 2022, is expected to reach USD 94.17 million by 2030, at a CAGR of 5.6% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Anticoagulant Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Vitamin K Antagonist (Warfarin), Non-VKA Oral Anticoagulants (NOACS), Heparin and LMWH, Thrombin Inhibitors (Dabigatran)), Therapeutic Areas (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Atrial Fibrillation, Heart Attack, Stroke, Unstable Angina, Hip Or Knee Replacement Surgery, Others), Route Of Administration (Oral, Parenteral), End User (Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Sanofi (France), Merck & Co., Inc (U.S.), Amneal Pharmaceuticals LLC. (U.K.), Alvogen (U.S.), Bausch Health Companies Inc. (Canada)
|
|
Market Opportunities
|
|
Market Definition
Anticoagulants are medications that aid in the prevention of blood clots. They are given to people at high risk of clotting to lower their chances of developing serious conditions such as strokes and heart attacks. A blood clot is a seal formed by blood to stop bleeding from wounds. If a blood clot prevents blood from flowing through a vessel, the affected area of the body will be deprived of oxygen and may cease to function properly. Aspirin, heparin, and warfarin are examples of anticoagulants.
Anticoagulant Market Dynamics
Drivers
- Increase in Elderly Population
People over the age of 65 are the world's fastest growing demographic segment, according to the World Health Organization (WHO). The proportion of the world's population over the age of 60 is expected to double between 2000 and 2050, rising from about 11% to 22%. According to the CDC, approximately 2% of people under the age of 65 have atrial fibrillation, while 9% of people over the age of 65 have the disease. It is also predicted that by 2030, nearly 12.1 million people will have atrial fibrillation. As a result, during the forecast period, the growing elderly population will drive the global anticoagulant reversal drugs market growth.
-
Increase in Hip and Knee Surgeries
The rising number of knee and hip replacement surgeries increases the likelihood of developing deep vein thrombosis (DVT). Surgery frequently results in prolonged immobility, which increases the risk of DVT due to decreased blood flow in the body. The number of surgical procedures performed on the elderly population has increased, according to the WHO 2016 report. The increased number of surgeries is expected to increase the likelihood of thromboembolic events following surgery, increasing patient demand for anticoagulant treatment.
Opportunities
- Rising Use of Warfarin
Some medications, such as blood thinners such as warfarin, heparin, and aspirin, can cause bleeding disorders. The anticoagulant agent used influences the high risk of bleeding. According to the National Center for Biotechnology Information (NCBI), bleeding in warfarin patients is estimated to be 15-20% each year. Warfarin-related life-threatening bleeding is expected to occur at a rate of 1-3% per year. As a result of the increased demand for anticoagulant therapies, potential opportunities for anticoagulant reversal agents are emerging.
Restraints/Challenges
- Side Effects of Medicines
Some medications can have a negative impact on the health of the population, particularly the elderly. It can sometimes cause excessive bleeding, and the higher dosage can cause a slew of complications. As a result, drug side effects limit the growth of the global anticoagulant reversal drugs market.
This anticoagulant market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anticoagulant market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2019, Bristol-Myers Squibb-Pfizer Alliance received safety and efficacy data for Eliquis for the treatment of venous thromboembolism in cancer patients. This efficacy data aided the company in providing physicians and patients with more opportunities to treat venous thromboembolism, resulting in increased product sales.
- In 2019, Cipla Inc. signed a partnership agreement with Wellthy Therapeutics Private Limited to provide digital therapeutics to cardiovascular disease patients. Because the company provides anticoagulants for the treatment of cardiovascular disease, this collaboration assisted the company in improving its platform for anticoagulant drugs by providing all anticoagulant therapy-related information through a digital platform.
Global Anticoagulant Market Scope
The anticoagulant market is segmented on the basis of drug class, therapeutic areas, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Vitamin K Antagonist (Warfarin)
- Non-VKA Oral Anticoagulants (NOACS)
- Eliquis
- Bevyxxa
- Xarelto
- Savaysa and lixiana
- pradaxa
- Heparin and LMWH
- Thrombin Inhibitors (Dabigatran)
Therapeutic Areas
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Atrial Fibrillation
- Heart Attack, Stroke
- Unstable Angina
- Hip or Knee Replacement Surgery
- Others
Route of Administration
- Oral
- Parenteral
End User
- Hospitals
- Clinics
- Home Healthcare
- Ambulatory Surgical Centers
- Others
Distribution Channel
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Anticoagulant Market Regional Analysis/Insights
The anticoagulant market is analyzed and market size insights and trends are provided by country, drug class, therapeutic areas, route of administration, end user and distribution channel as referenced above.
The countries covered in the anticoagulant market report are Brazil, Argentina and Rest of South America as part of South America.
North America dominates the anticoagulant market because of the well-developed healthcare infrastructure and favourable reimbursement policies in the region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the growing incidence of cancer such as bladder, esophagus, liver, pancreas, and others, high presence of major manufacturers across the U.S. Furthermore, technological advancements and rising foreign investment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The anticoagulant market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for anticoagulant market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the anticoagulant market. The data is available for historic period 2011-2021.
Competitive Landscape and Anticoagulant Market Share Analysis
The anticoagulant market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to anticoagulant market.
Some of the major players operating in the anticoagulant market are:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Lupin (India)
- Cipla Inc (India)
- Aurobindo Pharma (India)
- Sanofi (France)
- Merck & Co., Inc (U.S.)
- Amneal Pharmaceuticals LLC. (U.K.)
- Alvogen (U.S.)
- Bausch Health Companies Inc. (Canada)
SKU-